Cargando…

Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone

BACKGROUND: Maintaining antipsychotic therapy in psychosis is important in preventing relapse. Long-acting depot preparations can prevent covert non-adherence and thus potentially contribute to better patient outcomes. In this observational survey the main objective is to evaluate medication adheren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baylé, Franck Jean, Tessier, Arnaud, Bouju, Sophie, Misdrahi, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577258/ https://www.ncbi.nlm.nih.gov/pubmed/26396505 http://dx.doi.org/10.2147/PPA.S89748

Ejemplares similares

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louzã, Mário Rodrigues, et al.
Publicado: (2011)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
por: Hori, Hikaru, et al.
Publicado: (2018)

Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France
por: Limosin, Frédéric, et al.
Publicado: (2018)

Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection
por: Asseburg, Christian, et al.
Publicado: (2012)

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
por: Voss, Erica A., et al.
Publicado: (2015)

Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
por: Catalán, Rosa, et al.
Publicado: (2011)

Risperidone-Induced Amenorrhea in Floridly Psychotic Female
por: Shagufta, Shanila, et al.
Publicado: (2017)

RISPERIDONE VERSUS HALOPERIDOL IN ACUTE AND TRANSIENT PSYCHOTIC DISORDER
por: Chaudhuri, Bijoy Pratim, et al.
Publicado: (2000)

Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection
por: Samalin, L, et al.
Publicado: (2010)

Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
por: Nakamura, Yusuke, et al.
Publicado: (2019)

The cost associated with administering risperidone long-acting injections in the Australian community
por: Dalton, Andrew, et al.
Publicado: (2011)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
por: Singh, Dhiren, et al.
Publicado: (2009)

Management of Persistent Hyponatremia Induced by Long-acting Injectable Risperidone Therapy
por: Chowdhury, Waliul, et al.
Publicado: (2018)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada
por: Williams, Richard, et al.
Publicado: (2014)

Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection
por: El-Hage, Wissam, et al.
Publicado: (2010)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic
por: Chue, Pierre
Publicado: (2007)

An interventional pilot of customized adherence enhancement combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania
por: Mbwambo, Jessie, et al.
Publicado: (2022)

Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
por: Apiquian, Rogelio, et al.
Publicado: (2011)

Risperidone long-acting injection: a review of its long term safety and efficacy
por: Rainer, Michael K
Publicado: (2008)

Cumulative effects of risperidone long acting injection and narrative therapy in treating ethanol dependency
por: Trandafir, Maria Silvia
Publicado: (2010)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao, Yueren, et al.
Publicado: (2013)

Family psychoeducation to improve outcome in caregivers and patients with schizophrenia: a randomized clinical trial
por: Tessier, Arnaud, et al.
Publicado: (2023)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
por: Zhao, Mingjun, et al.
Publicado: (2023)

Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics
por: Ventriglio, Antonio, et al.
Publicado: (2019)

Use of Psychoeducation for Psychotic Disorder Patients Treated With Modern, Long-Acting, Injected Antipsychotics
por: Ventriglio, Antonio, et al.
Publicado: (2021)

Efficacy and Safety Profile of Risperidone Long-acting Injection in Adolescents in a Real-life Setting
por: Ardic, Ulku Akyol, et al.
Publicado: (2018)

Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone
por: Perlstein, Itay, et al.
Publicado: (2022)

A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss
por: Treur, Maarten, et al.
Publicado: (2009)

Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature
por: Fabrazzo, Michele, et al.
Publicado: (2021)

A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder
por: Demirkaya, Sevcan Karakoç, et al.
Publicado: (2017)

High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders
por: Auxilia, Anna Maria, et al.
Publicado: (2023)

Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone
por: Taurines, R., et al.
Publicado: (2022)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
por: Litman, Robert, et al.
Publicado: (2023)

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium
por: Lambert, Tim, et al.
Publicado: (2011)

Successful Treatment of Anorexia Nervosa in a 10-year-old Boy with Risperidone Long-acting Injection
por: Umehara, Hidehiro, et al.
Publicado: (2014)

Use of therapeutic drug monitoring of risperidone microspheres long-acting injection in hemodialysis: A case report
por: Tourtellotte, Rebecca, et al.
Publicado: (2019)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Associations of the SREBF2 Gene and INSIG2 Polymorphisms with Obesity and Dyslipidemia in Thai Psychotic Disorder Patients Treated with Risperidone
por: Vanwong, Natchaya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qb7llc0lrc0n3oogqs9dfnkr96